Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 245932
(a) an exclusive license (even as to Licensor) in the Territory under the Licensor Patent Rights, and Program Patent Rights to research, develop, make, have made, use, offer to sell, sell, have sold, import and export the Products in the Field;
(b) an exclusive license (even as to Licensor) in the Territory under the Licensor Know-How, the Licensor Program Know-How, and Licensorâ€™s rights in Joint Program Know-How to research, develop, make, have made, use, offer to sell, sell, have sold, import and export the Products in the Field; and
(c) an exclusive license (even as to Licensor) in the Territory under the Licensor Technology to research, develop, make, have made, use, offer to sell, sell, have sold, import and export the Surgical Instruments solely for use with, or in connection with the sale of, the Products in the Field.
Notwithstanding the license grants set forth above, Licensor shall retain those rights under the Licensor Technology that are necessary to perform Licensorâ€™s obligations under the Research Program and the Feasibility Studies in accordance with Agreement and to manufacture and supply clinical supplies and commercial supply of Product to Licensee and the scale up and transfer of manufacturing capabilities to Licensee in accordance with this Agreement and the Supply Agreement.
Non-Exclusive License Grant. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee a non-exclusive, royalty-free license in the Territory under the Licensor Program Technology, for any and all uses, including without limitation, to research, develop, make, have made, use, offer to sell, sell, have sold, import and export a product other than the Products.
TA Product shall mean the I-vation Platform incorporating a TA Compound as an active ingredient (which shall include without limitation the I-vation TA Product) and, for the purposes of Sections 5.2 through 5.6, that is in final form (i) for sale by prescription, over-the-counter or any other method, or (ii) for administration in a Clinical Trial or post-Marketing Authorization clinical trial.
I-vation Platform shall mean the Intravitreal Implant, together with the polymers applied as a coating thereto, for the purpose of containing and delivering sustained release of one or more active ingredients or therapeutic agents into the vitreous chamber of the eye, and any Improvements thereto,
Target shall mean a distinct, primary molecular target.
Surgical Instruments shall mean the Insertion Tool and/or the Extraction Tool, and any Improvements thereto.
The I-vation Intravitreal Implant is a drug delivery system capable of delivering a variety of drugs on a sustained release basis for well over a year, can be implanted in a minimally invasive procedure, and may be removed once the drug has been fully released. Currently, the majority of treatments being developed for AMD and DME require repeated injections into the eye, often with a suboptimal drug dosing profile. Replacing multiple injections with a single implant providing long-term, controlled drug release could represent a significant advance in therapeutic treatment, including improved patient compliance, reduced side effects and greater efficacy.
I-vation TA (a version of the I-vation implant formulated with the steroid triamcinolone acetonide) is being studied in a Phase I human clinical trial called STRIDE (Sustained Triamcinolone Release for Inhibition of Diabetic Macular Edema). The trial is assessing the safety and tolerability of the I-vation(TM) Intravitreal Implant with triamcinolone acetonide (TA) in patients with Diabetic Macular Edema (DME) under an Investigational New Drug application with the U.S. Food and Drug Administration.
IPSCIO Record ID: 256301
— an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Technology, the Licensor Program Technology, and the Licensor Confidential Information and
— an exclusive, even as to Licensor, royalty-bearing worldwide sublicense, with a right of further sublicense, under the Licensed University Technology, in each case to make, have made, use, sell or import Licensed Products, Devices and Formulations in the Territory in the Field; and,
— an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Patent Rights, and the Licensor Program Patent Rights and
— an exclusive, even as to Licensor, worldwide sublicense, with a right of further sublicense, under the Licensed University Patent Rights, in each case to make, have made, use, sell or import Licensed Products, Devices and Formulations in the Territory in the Field; and,
— a non-exclusive sublicense, without a right to further sublicense, to use the Licensor Trademarks with the Licensed Products, Devices and Formulations in the Territory in the Field.
Licensor has extensive expertise in designing and developing innovative ophthalmic drug delivery systems.
Medidur is a tiny injectable, non-erodible, intravitreal device for the treatment of Diabetic Macular Edema (DME), which can lead to blindness. The implant is injected into the back of the eye in an office setting rather than a surgical one. It releases a constant amount of drug and lasts between 18 to 36 months.
The Licensee's Compound means any composition of matter, including, small and large molecules, therapeutic proteins, polynucleotides, both double-stranded and singlestranded, and antibodies, or biosimilars.
Collaborative research and license agreement is for Licensorâ€™s controlled drug delivery technologies, including the MedidurTM technology, in ophthalmic applications.
IPSCIO Record ID: 294293
The joint research is for Implants for the treatment of dopamine associated states, meaning Biodegradable implant containing a dopamine modluating compound.
Licensor patents include Methods for manufacturing delivery systems and systems, and, Modulating burst and release profiles from coestruded implants by treating implant ends, and, Influencing drug release profiles from implants by selectively adjusting the location and amount of drug loading, and, Implant devices that differ by release profile and methods of making and using same.
IPSCIO Record ID: 2377
Products refers to Vitrase(TM) and Corneaplasty, certain proprietary technology relating to non-surgical therapeutic ophthalmic systems.
We are developing Vitrase, a proprietary formulation of hyaluronidase, for treatment of severe vitreous hemorrhage, a sight threatening condition, and diabetic retinopathy, the leading cause of adult blindness in the United States. Vitrase is currently in two Phase III clinical trials for treatment of severe vitreous hemorrhage. We are also conducting a pilot Phase IIa clinical trial of Vitrase in Mexico for treatment of diabetic retinopathy. Vitreous hemorrhage. A vitreous hemorrhage occurs when retinal blood vessels rupture and bleed into the vitreous humor, the clear, gel-like substance that fills the back of the eye between the lens and the retina. The blood from the hemorrhage can obscure vision and prevent ophthalmologists from seeing into the eye to diagnose or treat the cause of the hemorrhage. The only current treatment options are a watchful waiting period, during which no medical treatment is provided in the hope that the hemorrhage will clear on its own, and an invasive surgical procedure to remove the blood filled vitreous humor from the eye. Vitrase, when injected into the vitreous humor, causes the vitreous humor to liquefy and promotes clearance of vitreous hemorrhage. Based on market research we commissioned in February 1999, we believe that approximately one million cases of vitreous hemorrhage occur each year in the United States, Europe and Japan and that approximately half of these cases are candidates for treatment using Vitrase.